Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Jail study tests monthly shot to keep opioid treatment on track after release

NCT ID NCT06051890

Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests whether starting a monthly extended-release buprenorphine injection (Sublocade) in jail helps people with opioid use disorder stay on treatment after release. Two hundred men entering jail with a daily buprenorphine prescription will be randomly assigned to either switch to the monthly shot or stay on daily pills. Researchers will track how many leave jail with at least 7 days of buprenorphine in their system and how many continue treatment in the community.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extended-release buprenorphine (Sublocade injection)
What this could lead to
If successful, this could show that starting a monthly buprenorphine shot in jail helps more people continue their opioid use disorder treatment after release, reducing relapse and overdose risk.
What could go wrong
This is a single-site study with 200 men, so results may not apply to all populations. The intervention requires starting in jail, which may not be feasible everywhere. Risks include injection site reactions and potential for diversion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Incarcerated men able to provide written informed consent in English.\* * Unsentenced. * Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days. * Minimum anticipated jail stay is 4 days. * Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated). Exclusion Criteria: * Sentenced. * Allergy, hypersensitivity or medical contraindication to either medication. * Chronic pain requiring opioid pain management or other contraindicated medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid use disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baystate Health

    RECRUITING

    Springfield, Massachusetts, 01199, United States

  • Middlesex County House of Corrections

    RECRUITING

    New Brunswick, New Jersey, 08902, United States

  • NYU Langone Health - 180 Madison Ave

    RECRUITING

    New York, New York, 10016, United States

  • Tufts University Health Sciences

    RECRUITING

    Boston, Massachusetts, 02111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.